We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Emergex Vaccines Holding, a biotechnology company developing CD8+ priming set-point vaccines to prevent serious infectious diseases, announced that it has entered into an agreement with the George Mason University, based in Virginia, in the United States.